Table 3. Landmark OS in glioblastoma at first or second recurrence with Toca 511 and Toca FC versus lomustine.
Treatment groupToca 511 and Toca FC
(n = 27)
Lomustine
(n = 84)
P value
Landmark OS rate
OS696.0%61.8%<0.001
OS983.5%38.4%<0.001
OS1254.8%26.4%0.017
OS2429.1%9.1%0.065